Skip to content

The effect of intraoperative radiotherapy for locally advanced rectal cancer

The effect of intraoperative radiotherapy for locally advanced rectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014914
Enrollment
Unknown
Registered
2018-02-19
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

preoperative radiotherapy group:preoperative radiotherapy and operation
intraoperative radiotherapy group:intraoperative radiotherapy,operation and postoperative chemotherapy

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) infiltrative rectal adenocarcinoma; (2) more than 18 years-old; (3) WHO performance status inferior or equal to 2; (4) distance between anal margin and tumor less than 12 cm; (5) T3 with MRF or EMVI positive or T4 or N+ and M0 according to radiology; (6) patients treated with a preoperative radiotherapy with good general and visceral conditions allowing surgery and possible prolonged operative time.

Exclusion criteria

Exclusion criteria: (1) the pathological diagnosis is not adenocarcinoma or multiform pathological types; (2) with clinical symptoms requiring emergency surgery for treatment (complete obstruction, bleeding, intestinal perforation); (3) have received chemotherapy treatment or combined with other the anti-tumor treatment; (4) with serious basic diseases: heart disease, kidney failure, severe liver dysfunction or liver failure, coagulation dysfunction or oral dose of anticoagulant drugs; (5) any other contraindications for the use of radiotherapy; (6) patients with pregnancy; (7) with other detectable metastasis; (8) multiple primary colon cancer patients, or suffer from other malignant tumors, or have been systematic chemotherapy.

Design outcomes

Primary

MeasureTime frame
safety;postoperative complications;operative duration;

Secondary

MeasureTime frame
R0 resection;positive lymph nodes;TRG;The proportion of patients receiving adjuvant chemotherapy after surgery;rate of anus preservation;????????;rate of recurrence;DFS;3 years survival rate;

Countries

China

Contacts

Public ContactXishan Wang,Zheng Jiang

Cancer Hospital, Chinese Academy of Medical Sciences

dr.jiangzheng@gmail.com+86 18810817803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026